Sputnik Light Covid vaccine receives DCGI nod for phase III bridging trials in India

Mangalore Today News Network

New Delhi, Sep 15, 2021: Sputnik’s single-dose Covid-19 vaccine, Sputnik Light, has received the approval of the Drugs Controller General of India (DCGI) to conduct phase III bridging trials on the Indian population.

 

The Subject Expert Committee (SEC) of the DCGI recommended the phase III bridging trials for Sputnik Light.

Earlier in July, the Subject Expert Committee of DCGI had refused to grant emergency-use authorisation to Sputnik-Light, ruling out the need for the conduct of the phase-3 trial of the Russian vaccine in the country.

A recent study published in The Lancet showed that Sputnik Light showed 78.6-83.7 per cent efficacy against Covid-19, significantly higher than most two-shot vaccines. The study was conducted on at least 40,000 elderly people in Argentina.

Sputnik Light also reduced hospitalisations among the target population at 82.1-87.6 per cent, the study said.

Courtesy:India Today